Results 181 to 190 of about 73,583 (263)

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

The impact of COVID-19 on longevity trends and disparities among Native Americans and Whites in the Four Corners States. [PDF]

PLoS One
Lenarz AM, Park H, Roberts MT, Pan A, Hofmann ET, Reither EN.   +5 more
europepmc   +1 more source

Correction to “The Dynamic Evolution of Lipid Profiles Following Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis”

Portal Hypertension &Cirrhosis, EarlyView.
wiley   +1 more source

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source

Nurse-Led Clinic for Patients With Decompensated Liver Cirrhosis. [PDF]

JGH Open
Kelstrup EE, Andersen SH, Poulsen TL, Thomsen KL, Kazankov K, Bager P.   +5 more
europepmc   +1 more source

Correction to “Chinese Registry on Transjugular Intrahepatic Portosystemic Shunts (CN‐TIPS): Protocol for a Registry‐Based, Prospective Prognostic Study”

Portal Hypertension &Cirrhosis, EarlyView.
wiley   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases. [PDF]

Int J Nanomedicine
Meng C, Liu M, Qi Q, Cao L, Lei Q, Liu X, Wang M.   +6 more
europepmc   +1 more source

Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Hepatology Research, EarlyView.
Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori, Kazuhiro Yamamoto, Hiroshi Aoi, Yusuke Koizumi, Makoto Kuromatsu, Aiko Fukui, Hiroyo Okamoto, Atsushi Hirata, Kentaro Shinmori, Yuki Imanaka, Miyu Namba, Keisuke Nakanishi, Syunsuke Kitamura, Hideo Tsushima, Ikuko Yano, Kei Moriya, Masaru Matsui, Shigeki Ikushima   +17 more
wiley   +1 more source